Dr. Matthew Davids On Advances in CLL

Video

In Partnership With:

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances inchronic lymphocytic leukemia (CLL) treatment.

Several novel therapies have been approved recently for CLL, including obinutuzumab, ibrutinib, ofatumumab, and idelalisib. Since many of these novel therapies only elicit a partial response, combining them may be a better plan for developing a deeper, more full response, says Davids. Another benefit of combining these agents is that many of them have non-overlapping toxicities and complementary efficacy.

Davids says in practice, these newly approved agents will be used more in older patients in an attempt to move away from chemotherapy, while a combination of chemo-immunotherapy may be more ideal for younger patients.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD